Immunosuppression in cancer poses challenges for immunotherapy and highlights the vulnerability of immunocompromised patients to viral infections. This study explored how Chikungunya virus (CHIKV) infection potentially inhibits B16-F10 melanoma-induced immunosuppressive effects on T cells and RAW 264.7 macrophages.
View Article and Find Full Text PDFToll like receptor 4 (TLR4), a pathogen-associated molecular pattern (PAMP) receptor, is known to exert inflammation in various cases of microbial infection, cancer and autoimmune disorders. However, any such involvement of TLR4 in Chikungunya virus (CHIKV) infection is yet to be explored. Accordingly, the role of TLR4 was investigated towards CHIKV infection and modulation of host immune responses in the current study using mice macrophage cell line RAW264.
View Article and Find Full Text PDFThe transient receptor potential vanilloid 1 (TRPV1) channel is a thermo-sensitive, polymodal cation channel. An increase in intracellular calcium (Ca) is essential for T-cell responses. Similarly, various immunosuppressive agents are also reported to induce Ca influx.
View Article and Find Full Text PDFTransient receptor potential (TRP) channels are a superfamily of cation-specific permeable channels primarily conducting Caions across various membranes of the cell. The perturbation of the Ca homeostasis is the hallmark of viral infection. Viruses hijack the host cell Ca signaling, employing tailored Ca requirements via TRP channels to meet their own cellular demands.
View Article and Find Full Text PDFAntimicrob Agents Chemother
January 2022
Chikungunya virus (CHIKV) has reemerged as a global public health threat. The inflammatory pathways of the renin-angiotensin system (RAS) and peroxisome proliferator-activated receptor-gamma (PPAR-γ) are usually involved in viral infections. Thus, telmisartan (TM), which is known to block the angiotensin 1 (AT1) receptor and activate PPAR-γ, was investigated for activity against CHIKV.
View Article and Find Full Text PDF